Immunosuppression in Chronic Autoimmune Neurological Disorders during the COVID-19 Pandemic
Neurology
; 98(18 SUPPL), 2022.
Article
in English
| EMBASE | ID: covidwho-1925134
ABSTRACT
Objective:
To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS).Background:
NA Design/Methods:
We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID-19, hospitalization, intubation, and mortality among the patients with aNMD and MS.Results:
A total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group;however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011).Conclusions:
IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings.
adult; clinical research; conference abstract; controlled study; coronavirus disease 2019; electronic medical record; female; global health; hospitalization; human; immunosuppressive treatment; immunotherapy; infection risk; International Classification of Diseases; intubation; major clinical study; male; mortality; multiple sclerosis; myasthenia gravis; myositis; neurologic disease; neuromuscular disease; neuropathy; pandemic; physician; practice guideline
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Neurology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS